Tirzepatide News
Every article we’ve published on Tirzepatide, newest first — 15 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
GLP-1 Muscle Loss Study Will Track DXA Scans and Grip Strength
An observational GLP-1 muscle loss study posted to ClinicalTrials.gov on September 22 will measure body composition with DXA scans plus physical function tests in adults already starting GLP-1 receptor agonist therapy. It lands alongside a new review in Maturitas that flags muscle health as one of the open questions for semaglutide in postmenopausal women.
Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance
The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.
GLP-1 After Bariatric Surgery: Phase 4 Trial Now Recruiting
Two academic randomized trials are now attacking the same unanswered question: what should happen to GLP-1 after bariatric surgery. One is recruiting 150 patients in Missouri; the other, GRABS, has just published its rationale, design and baseline characteristics. For anyone tracking a GLP-1 protocol through a planned surgery, this is the evidence that does not yet exist.
NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide
A newly posted NNC0662-0419 phase 2 trial record shows Novo Nordisk testing an experimental blood-sugar medicine head-to-head against semaglutide in 270 people with type 2 diabetes. For anyone following what comes after the current generation of GLP-1 drugs, the choice of comparator is the detail worth noting.
Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins
A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.
Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes
A new semaglutide smoking cessation trial listed on ClinicalTrials.gov is recruiting 100 participants with diabetes to test the GLP-1 receptor agonist as an add-on to nicotine replacement therapy. It is one of several studies registered or published this week pushing incretin drugs well beyond weight and glucose control.
Enobosarm GLP-1 Trial: 239-Patient Muscle Study Closes Enrollment
A ClinicalTrials.gov update dated September 4, 2026 shows the enobosarm GLP-1 trial has finished enrolling 239 participants and moved into its active, non-recruiting phase. It is one of the clearest signals yet that drug development around incretin therapy has shifted from how much weight comes off to what tissue comes off with it.
Stopping and Restarting Tirzepatide Gets Its Own Clinical Trial
Registry records updated in early September 2026 show researchers are now studying stopping and restarting tirzepatide as a deliberate, measured event rather than an accident of insurance or supply. A separate Phase 3a trial is testing early semaglutide re-initiation after bariatric surgery in adolescents.
CagriSema vs Tirzepatide Trial Completes in Type 2 Diabetes
A phase 3 CagriSema vs tirzepatide trial in more than a thousand adults with type 2 diabetes has moved to completed status on the federal trial registry, setting up the first direct comparison between Novo Nordisk's investigational amylin-GLP-1 combination and Eli Lilly's approved dual agonist. Two separate phase 3 trials of cagrilintide on its own also appeared in the same registry update.
Weight Regain After Stopping Semaglutide Mapped in New Meta-Analysis
A reconstructed aggregate-data meta-analysis published in Endocrinology, Diabetes & Metabolism models weight regain after stopping semaglutide or tirzepatide, and it landed the same week as a separate analysis of glycaemic changes after semaglutide discontinuation in type 1 diabetes. Together they sharpen a question that matters to anyone on a GLP-1 protocol: what happens when the injections stop.
Semaglutide Opioid Use Disorder Trial Opens Phase 2 Enrollment
A Phase 2 semaglutide opioid use disorder trial is now recruiting 200 adults in outpatient addiction treatment, testing whether the GLP-1 receptor agonist helps people refrain from illicit opioids. It is one of two new GLP-1 trials registered this week that push these drugs well outside diabetes and weight management.
Semaglutide Muscle Loss Study Joins New Trials on Lean Mass
Three separate research entries indexed in the past week — a longitudinal semaglutide muscle loss study, a review of skeletal muscle health during incretin-based therapy, and a newly posted Phase 4 trial — all converge on the same unanswered question. For anyone tracking a GLP-1 protocol, lean mass is moving from forum speculation to formal endpoint.
GLP-1 Non-Responders: New Review Asks If Response Can Be Predicted
A review indexed this month in Diabetes, Obesity & Metabolism takes on one of the least discussed features of incretin therapy: the substantial minority of people who get far less from it than trial averages suggest. Alongside new subgroup work on tirzepatide in women with polycystic ovary syndrome and a paper on muscle mass during incretin-based weight loss, the question of what separates GLP-1 non-responders from responders is moving from anecdote to research agenda.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Tirzepatide Combination Therapy Trials: Four New Add-On Studies
Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.